about
Treatment for postpolio syndromeTreatment for postpolio syndromeTreatment for postpolio syndromeInternational consensus guidance for management of myasthenia gravis: Executive summaryGuidelines for the treatment of autoimmune neuromuscular transmission disorders.EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force.Guidelines for treatment of autoimmune neuromuscular transmission disorders.Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.Are MRI high-signal changes of alar and transverse ligaments in acute whiplash injury related to outcome?Arthrogryposis multiplexa congenita: an epidemiologic study of nearly 9 million births in 24 EUROCAT registers.The reversibility of phenytoin-induced IgA deficiency.Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.Autoimmunity against the ryanodine receptor in myasthenia gravis.EEG background activity described by a large computerized database.Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors.Striational antibodies in myasthenia gravis: reactivity and possible clinical significance.Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort studyEFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development.Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.Myasthenia gravis: a review of available treatment approaches.Long term outcome after poliomyelitis in different health and social conditions.Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies.Psychiatric Comorbidity, Social Aspects and Quality of Life in a Population-Based Cohort of Expecting Fathers with EpilepsyMyasthenia gravis: clinical, immunological, and therapeutic advances.Pregnancies and deliveries in patients with Charcot-Marie-Tooth disease.Complicating autoimmune diseases in myasthenia gravis: a review.Titin and ryanodine receptor antibodies in myasthenia gravis.Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force.Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin.A retrospective view on research in neuroscience in Norway.Exposure to antiepileptic drugs in utero and child development: a prospective population-based study.Autoimmune myasthenia gravis.Clinical aspects of myasthenia explained.Heat-shock proteins in clinical neurology.Serum levels of matrix metalloproteinases: implications in clinical neurology.Pregnancy complications in patients with epilepsy.Traumatic spinal cord injuries--incidence, mechanisms and course.Myasthenia and the neuromuscular junction.EFNS/ENS Guidelines for the treatment of ocular myasthenia.
P50
Q24187934-24488167-5EA7-4C0C-AB86-7ED743A95384Q24236577-F6F4707C-033A-49C9-9D16-72F34A415327Q24240648-60430900-0F24-4B87-8242-EA4A507FAFB7Q26746047-66E05B31-A4B0-4643-B7C6-F11E0A63FDE8Q30819532-BBB14EA7-4975-4A6B-83B9-0703122EECC9Q31050648-709302AD-D0F5-4969-969C-5679D8B36666Q33558942-076B5839-6A39-46E0-9842-E9067D43D207Q33732795-84526203-8C06-4BE8-83D2-1525D3A53CACQ33744501-9632BE2F-36C7-4A60-8FA1-3730A47D49E0Q34225035-01D1477F-1DB5-43EB-A18E-A075A3BD4121Q34249518-222C0D3B-DE3D-4745-BA4B-0A78EF17E819Q34270872-60142231-F753-4CDE-83E0-D4B6BCC90F91Q34285884-03340D08-E541-4F60-91CA-32D3AB7DFCF1Q34307689-E1614654-8648-4448-A4A9-1E0F44202E58Q34310349-62916E60-09AF-4BFE-8841-39DB6D0E8C49Q34402927-C69FD873-1F85-46D7-9968-C06B8011BE2CQ34548870-65DC150D-F841-42FE-B2A1-876B1FB35A5DQ34597256-CA6ED128-A35B-4B02-B1EB-3EF2C44C0DC1Q34612356-417A8717-98B3-46A9-AC74-DF8007E1A5C3Q35239122-EBC609A5-0E21-45A8-9CAA-0D740B0F215CQ35293574-FDD89B20-C1DB-45A7-85FF-D008C47DD6C4Q35411674-B2A0B115-E89A-4B55-93B1-56C83BDC07A5Q35573396-2993E7E0-489B-4AB2-B70F-5F5542AF085FQ35861194-5F87DE02-465A-403D-AF14-E71012ADA470Q36006116-E7A46F65-D625-4BE1-9AFD-424674626297Q36033827-86664983-E620-4340-B80A-B264911C7C69Q36192435-2D206A04-F592-4594-999C-0D10C6AE1AA9Q36459493-25BF50FF-C7FE-4D26-BB3D-94303EFB59FFQ36575967-915A7672-84E5-4C4F-8DA7-5AE990117318Q36766982-9B00D374-BC25-4E0B-A0A1-509EA23D63C7Q37148478-CE2F9492-8283-4DEC-90BF-F3A470BD7D25Q37153982-E31339B3-0E3B-495D-8862-A5F92A8B3811Q37409490-2F8FFEE7-860D-42C2-9D21-CCBCB5423CC4Q37727997-FFD400FB-AE7D-4FB5-AC76-4FD5EC22A503Q37901289-21640AE5-73F0-4440-ADED-20DE2688180DQ37977361-74E3101F-4E8A-4D70-8638-328FD88EFA22Q37983445-A24FA8A6-7285-4196-9FCF-D3BCDF0FF43FQ38003321-90795F6B-65B4-4E94-A07D-972EFAE4DF86Q38034658-E149127B-B8D2-420B-A0DD-43020FDBA8D2Q38182650-93D69F14-879A-467E-9422-50FB48BD2E73
P50
description
Noors professor
@nl
Norwegian professor
@en
norsk professor
@nb
ollamh Ioruach
@ga
name
Nils Erik Gilhus
@ast
Nils Erik Gilhus
@da
Nils Erik Gilhus
@de
Nils Erik Gilhus
@en
Nils Erik Gilhus
@es
Nils Erik Gilhus
@fr
Nils Erik Gilhus
@ga
Nils Erik Gilhus
@nb
Nils Erik Gilhus
@nl
Nils Erik Gilhus
@nn
type
label
Nils Erik Gilhus
@ast
Nils Erik Gilhus
@da
Nils Erik Gilhus
@de
Nils Erik Gilhus
@en
Nils Erik Gilhus
@es
Nils Erik Gilhus
@fr
Nils Erik Gilhus
@ga
Nils Erik Gilhus
@nb
Nils Erik Gilhus
@nl
Nils Erik Gilhus
@nn
prefLabel
Nils Erik Gilhus
@ast
Nils Erik Gilhus
@da
Nils Erik Gilhus
@de
Nils Erik Gilhus
@en
Nils Erik Gilhus
@es
Nils Erik Gilhus
@fr
Nils Erik Gilhus
@ga
Nils Erik Gilhus
@nb
Nils Erik Gilhus
@nl
Nils Erik Gilhus
@nn
P106
P214
P21
P214
P2287
P27
P31
P496
0000-0001-6522-5102
P569
1950-01-01T00:00:00Z
P7859
lccn-n2006180107